Transforming the future of personalized cancer therapy
Our advanced technologies focus on the isolation and characterization of circulating tumor cells (CTCs) from the blood of cancer patients, laying the foundation for precision medicine. Our goal is to improve cancer care by conducting in-depth analyses of CTCs and providing tailored treatment plans based on the unique characteristics of each patient's cancer.
Tzu Cancer Therapeutics is a biotechnology startup, inspired by the ancient Chinese philosopher and strategist Sun Tzu. Over 2,500 years ago, in the Art of War, he emphasized that knowing one’s enemy is essential to winning every battle. We believe that precise knowledge of the cells that cause metastases is the foundation of effective personalized cancer treatment.
Tzu was founded in July 2024 by Ronald Plasterk, Ronald Brus, and René Beukema. The goal of the company is to develop personalized therapies based on the molecular analysis of Circulating Tumor Cells (CTCs).
Our company
“Know the enemy and know yourself; in a hundred battles you will never be defeated”
— Sun Tzu (544 - 596 BC) - The Art of War
-
Current cancer therapies often fail because they do not accurately reflect the composition of metastasizing cells.
-
Tzu’s technology focuses on the detailed characterization of CTCs t develop therapies that can effectively target and eliminate these cells, thereby preventing metastasis. Our technology helps in early detection, reveal tumor heterogeneity and capture tumor evolution.
-
Cancer patients, starting with breast and prostate cancer, who require personalized cancer treatments strategies. In principle, the approach can be applied to most or all tumor types.